Ascendis制药 ASND 深 沪
已收盘 12-19 16:00:00 美东时间
199.87
+0.070
+0.04%
华盛通- 最 高229.94
- 今 开200.67
- 成交量 104.78万股
- 最 低 192.28
- 昨 收 199.80
- 总市值 111.53亿
- 52周最高 229.94
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 118.03
- 委 比 50.51%
- 总股本 5580.36万
- 历史最高 229.94
- 量 比 1.32
- 振 幅 18.85%
- 历史最低 1.10
- 每 手 1
- 风险率 26.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.
12-09 21:16
港股创新药涨疯了，常山直接2个20cm！东吴：2025是3年行情元年
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：金石杂谈） 转自：金石杂谈 6月9日，创新药继续狂飙，港股创新药，尤其B类医药股，纷纷10cm以上大肉，中国抗体、欧康维视生物、金斯瑞生物、四环医药等纷纷大涨。 尤其下面这张图，含金量会不断上升，百济、恒瑞、信达、翰森等都是创新药龙头。 不知不觉，在港股创新药暴涨之际，A股创新药概念同样暴涨，星昊医药暴涨26%，海辰药业、常山制药直接20cm涨停。 常山药业连续2日20cm，今年以来暴涨160%，公司股价暴涨背后，到底涨什么？有人说是减肥药，也有人说是创新药；而6月6日的龙虎榜显示，前五席位有三个是机构，可见...
06-10 00:16
港股创新药涨疯了，常山直接2个20cm！东吴：2025是3年行情元年
6月9日，创新药继续狂飙，港股创新药，尤其B类医药股，纷纷10cm以上大肉，中国抗体、欧康维视生物、金斯瑞生物、四环医药等纷纷大涨。 尤其下面这张图，含...
06-09 16:52
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
Ascendis Pharma announces positive interim results from the COACH Trial, showing combination treatment with TransCon CNP and TransCon hGH improved growth and proportionality in children with achondroplasia, with a favorable safety profile. A conference call will discuss the findings today.
06-09 11:00
医药主题产品霸榜！对话知名基金经理万民远：为什么他说当下创新药“大部分都是纯炒”
2025年创新药板块迎来爆发式行情。 A股创新药指数年内大涨超20%，港股创新药指数涨幅接近50%，百济神州、康方生物等龙头股表现抢眼。汇添富国证港股通创新药...
06-05 22:13
FDA Accepts TransCon® CNP NDA for Priority Review
The FDA has accepted for priority review TransCon CNP's New Drug Application for treating children with achondroplasia, with a PDUFA goal date of November 30, 2025. The weekly treatment demonstrated significant growth benefits and improved health outcomes beyond linear growth compared to placebo, with a safety profile similar to placebo. The FDA's priority review highlights the potential of TransCon CNP to address serious complications of achondroplasia.
06-02 12:00
Ascendis Pharma Commences Public Offering Of $300M Of ADSs
All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the public offering price, less the
2024-09-19 04:05
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
2024-09-17 00:31
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on M...
2024-09-16 22:03
Ascendis Pharma Says FDA Granted Orphan Drug Exclusivity To YORVIPATH For Treatment Of Hypoparathyroidism In Adults
YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. Hypoparathyroidism is a rare endocrine disease
2024-09-12 05:39
